Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

55.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.5K
Mutations01:35

Mutations

45.4K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
45.4K
Mutations01:39

Mutations

95.9K
Overview
95.9K
Mutations01:39

Mutations

13.6K
13.6K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

2.8K
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Mar 19, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

New Driver Mutations Detected in NSCLC

    Cancer Discovery
    |June 15, 2016
    PubMed
    Summary

    Researchers discovered new mutations in non-small cell lung cancer (NSCLC) that can guide the development of targeted drugs and immunotherapies. These findings also reveal crucial differences between major NSCLC subtypes for future treatment strategies.

    Area of Science:

    • Oncology
    • Genetics
    • Translational Medicine

    Background:

    • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
    • Identifying specific genetic alterations is crucial for developing effective targeted therapies.
    • Understanding subtype-specific differences in NSCLC is essential for optimizing treatment approaches.

    Purpose of the Study:

    • To identify novel driver mutations in non-small cell lung cancer.
    • To explore the molecular differences between major NSCLC subtypes.
    • To provide insights for the development of new targeted drugs and immunotherapies for NSCLC.

    Main Methods:

    • Comprehensive genomic profiling of NSCLC patient samples.
    • Comparative analysis of mutation profiles across different NSCLC subtypes.

    More Related Videos

    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
    05:17

    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

    Published on: October 10, 2025

    500
    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.8K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    25.2K
    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
    05:17

    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

    Published on: October 10, 2025

    500
    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    1.8K
  • Bioinformatic analysis to identify potential therapeutic targets.

    • Main Results:

    • Discovery of additional driver mutations in NSCLC.
    • Characterization of key molecular distinctions between two major NSCLC subtypes.
    • Identification of potential targets for novel drug development and immunotherapy.

    Conclusions:

    • The identified driver mutations offer new avenues for targeted drug development in NSCLC.
    • Understanding NSCLC subtype differences can refine therapeutic strategies.
    • These findings contribute to advancing personalized medicine for lung cancer patients.